ReviewFrontiers in immunology2026
JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) management has moved from symptom control toward treat-to-target strategies, yet many patients with ulcerative colitis or Crohn's disease remain difficult to treat after primary non-response, secondary loss of response, or intolerance to advanced therapy. Upadacitinib, an oral Janus kinase 1 (JAK1)-preferential inhibitor, has shown clinically meaningful efficacy in both ulcerative colitis and Crohn's disease, including biologic-experienced populations. In this Perspective, we propose rapid immune recalibration as a hypothesis-generating clinical model for interpreting rapid inflammatory control following JAK1-preferential inhibition in selected patients with inflammation-dominant refractory IBD, rather than as an established biological mechanism or evidence of a durable immune reset. Recalibration is defined here as an early pharmacologically induced shift in the intensity and balance of convergent cytokine signaling, not as immune homeostasis restoration, mucosal healing, transmural repair, fibrosis reversal, or proven disease modification. We distinguish established clinical evidence from mechanistic rationale and from unvalidated downstream hypotheses, including barrier stabilization, microbiome change, anti-fibrotic potential, and biomarker-guided positioning. We also outline measurable clinical criteria, feasible biomarkers, exploratory translational endpoints, and safety boundaries that should guide future testing of this framework. This more bounded interpretation may help inform future efforts to move refractory IBD treatment from empirical drug switching toward mechanism-informed therapeutic choice without overstating the current evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.